{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T18:03:00Z","timestamp":1784484180218,"version":"3.55.0"},"posted":{"date-parts":[[2026,7,7]]},"group-title":"In Review","reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,1]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>BACKGROUND:<\/bold>\n                  Impella and IABP are widely used temporary mechanical circulatory support devices in cardiogenic shock (CS). While the Impella is used as an initial support or after IABP as escalation strategy, comparative data on these two strategies remains limited.\n                  <bold>METHODS:<\/bold>\n                  Using ICD-10 codes in the 2016-2022National Inpatient Sample (NIS) database, we identified patients with primary diagnosis of CS who received Impella support and divided in two groups: direct Impella use and escalation from IABP to Impella. Propensity score matching was performed to adjust for confounding.\n                  <bold>RESULTS:<\/bold>\n                  Among 107,007 patients were included, 700 (6.5%) underwent IABP-to-Impella escalation strategy. Before matching, the direct Impella use had significantly shorter length-of-stay (LOS) 11.4\u00b113.97 vs. 19.28\u00b120.70 days,\n                  <italic>P<\/italic>\n                  &lt;0.001), lower total hospital charges ($441,236 vs. $726,021,\n                  <italic>P<\/italic>\n                  &lt;0.001) and fewer transfusions (14.8% vs. 20.6%,\n                  <italic>P<\/italic>\n                  &lt;0.001), while the escalation Impella use after IABP had higher rates of durable left ventricular assist device (LVAD) implantation (7.9% vs. 2.2%,\n                  <italic>P<\/italic>\n                  &lt;0.001) and rates of orthotopic heart transplant (OHT) (5.0% vs. 1.2%,\n                  <italic>P<\/italic>\n                  &lt;0.001). After matching, the direct Impella group still had shorter LOS (13.77\u00b117.21 vs 19.22\u00b120.70 days,\n                  <italic>P<\/italic>\n                  &lt;0.001), lower total costs ($478,526 vs. $725,276,\n                  <italic>P<\/italic>\n                  &lt;0.001), and fewer transfusions (1.9% vs. 4.9%,\n                  <italic>P<\/italic>\n                  =0.026), while escalation Impella use after IABP still had higher rates of LVAD implantation (7.7% vs. 3.0%,\n                  <italic>P<\/italic>\n                  &lt;0.001) and OHT (4.9% vs. 1.9%,\n                  <italic>P<\/italic>\n                  =0.003).\n                  <bold>CONCLUSIONS:<\/bold>\n                  In cardiogenic shock, direct and escalation Impella use were associated with similar in-hospital mortality, but direct use was linked to shorter hospital stays and lower costs, highlighting potential benefits in resource utilization and efficiency.\n                <\/p>","DOI":"10.21203\/rs.3.rs-9887872\/v1","type":"posted-content","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T12:47:21Z","timestamp":1783428441000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Outcomes of Direct Impella Use vs. Intra-Aortic Balloon Pump (IABP)-to- Impella Escalation Strategy in Cardiogenic Shock: Insights from the National Inpatient Sample"],"prefix":"10.21203","author":[{"given":"Xiaojia","family":"Lu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Shantou University Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Patel","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romani","family":"Wahba","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cai","sequence":"additional","affiliation":[{"name":"Mathematical Sciences, Worcester Polytechnic Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Khalil","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Racha","family":"Ghousaini","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirollos","family":"Gabrah","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Tchoukina","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Smallfield","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C","family":"Kontos","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur B","family":"Shah","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyang","family":"Li","sequence":"additional","affiliation":[{"name":"The Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.2021.18323","article-title":"Cardiogenic Shock After Acute Myocardial Infarction: A Review","volume":"326","author":"Samsky MD","year":"2021","unstructured":"Samsky MD, Morrow DA, Proudfoot AG, Hochman JS, Thiele H, Rao SV. Cardiogenic Shock After Acute Myocardial Infarction: A Review. JAMA. 2021;326:1840\u201350.","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4244\/EIJ-D-20-01296","article-title":"Management of cardiogenic shock","volume":"17","author":"Thiele H","year":"2021","unstructured":"Thiele H, de Waha-Thiele S, Freund A, Zeymer U, Desch S, Fitzgerald S. Management of cardiogenic shock. EuroIntervention. 2021;17:451\u201365.","journal-title":"EuroIntervention"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2022.04.049","article-title":"Criteria for Defining Stages of Cardiogenic Shock Severity","volume":"80","author":"Kapur NK","year":"2022","unstructured":"Kapur NK, Kanwar M, Sinha SS, Thayer KL, Garan AR, Hernandez-Montfort J, et al. Criteria for Defining Stages of Cardiogenic Shock Severity. J Am Coll Cardiol. 2022;80:185\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e020085","DOI":"10.1161\/JAHA.120.020085","article-title":"Phenotyping Cardiogenic Shock","volume":"10","author":"Zweck E","year":"2021","unstructured":"Zweck E, Thayer KL, Helgestad OKL, Kanwar M, Ayouty M, Garan AR, et al. Phenotyping Cardiogenic Shock. J Am Heart Assoc. 2021;10:e020085.","journal-title":"J Am Heart Assoc"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e009279","DOI":"10.1161\/CIRCHEARTFAILURE.121.009279","article-title":"Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes","volume":"15","author":"Sinha SS","year":"2022","unstructured":"Sinha SS, Rosner CM, Tehrani BN, Maini A, Truesdell AG, Lee SB, et al. Cardiogenic Shock From Heart Failure Versus Acute Myocardial Infarction: Clinical Characteristics, Hospital Course, and 1-Year Outcomes. Circ Heart Fail. 2022;15:e009279.","journal-title":"Circ Heart Fail"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1208410","article-title":"Intraaortic balloon support for myocardial infarction with cardiogenic shock","volume":"367","author":"Thiele H","year":"2012","unstructured":"Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287\u201396.","journal-title":"N Engl J Med"},{"key":"ref7","first-page":"297","article-title":"The outcomes of intra-aortic balloon pump usage in patients with acute myocardial infarction: a comprehensive meta-analysis of 33 clinical trials and 18,889 patients","volume":"10","author":"Fan ZG","year":"2016","unstructured":"Fan ZG, Gao XF, Chen LW, Li XB, Shao MX, Ji Q, et al. The outcomes of intra-aortic balloon pump usage in patients with acute myocardial infarction: a comprehensive meta-analysis of 33 clinical trials and 18,889 patients. Patient Prefer Adherence. 2016;10:297\u2013312.","journal-title":"Patient Prefer Adherence"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ahj.2017.11.016","article-title":"Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock","volume":"199","author":"Hsu S","year":"2018","unstructured":"Hsu S, Thiruvengadam SK, Sciortino CM, Russell SD, Schulman SP. Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. Am Heart J. 2018;199:181\u201391.","journal-title":"Am Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1161\/CIRCULATIONAHA.119.044007","article-title":"The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support","volume":"141","author":"Amin AP","year":"2020","unstructured":"Amin AP, Spertus JA, Curtis JP, Desai N, Masoudi FA, Bach RG, et al. The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support. Circulation. 2020;141:273\u201384.","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","article-title":"Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock","volume":"390","author":"M\u00f8ller JE","year":"2024","unstructured":"M\u00f8ller JE, Engstr\u00f8m T, Jensen LO, Eiskj\u00e6r H, Mangner N, Polzin A, et al. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock. N Engl J Med. 2024;390:1382\u201393.","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.healun.2024.05.015","article-title":"Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group","volume":"43","author":"Fried J","year":"2024","unstructured":"Fried J, Farr M, Kanwar M, Uriel N, Hernandez-Montfort J, Blumer V, et al. Clinical outcomes among cardiogenic shock patients supported with high-capacity Impella axial flow pumps: A report from the Cardiogenic Shock Working Group. J Heart Lung Transpl. 2024;43:1478\u201388.","journal-title":"J Heart Lung Transpl"},{"key":"ref12","article-title":"Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock","author":"Abraham J","year":"2025","unstructured":"Abraham J, Anderson M, Silvestry S, Soltesz EG, Ono M, Mody K et al. Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock. J Card Fail. 2025.","journal-title":"J Card Fail"},{"key":"ref13","first-page":"1","article-title":"First-Line Support by Intra-Aortic Balloon Pump in Non-Ischaemic Cardiogenic Shock in the Era of Modern Ventricular Assist Devices","volume":"138","author":"Uil CA","year":"2017","unstructured":"den Uil CA, Galli G, Jewbali LS, Caliskan K, Manintveld OC, Brugts JJ, et al. First-Line Support by Intra-Aortic Balloon Pump in Non-Ischaemic Cardiogenic Shock in the Era of Modern Ventricular Assist Devices. Cardiology. 2017;138:1\u20138.","journal-title":"Cardiology"},{"key":"ref14","first-page":"101177","article-title":"National Trends for Temporary Mechanical Circulatory Support Utilization in Patients With Cardiogenic Shock From Decompensated Chronic Heart Failure: Incidence, Predictors, Outcomes, and Cost","volume":"2","author":"Malik A","year":"2023","unstructured":"Malik A, Basu T, VanAken G, Aggarwal V, Lee R, Abdul-Aziz A, et al. National Trends for Temporary Mechanical Circulatory Support Utilization in Patients With Cardiogenic Shock From Decompensated Chronic Heart Failure: Incidence, Predictors, Outcomes, and Cost. J Soc Cardiovasc Angiogr Interv. 2023;2:101177.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s12928-024-00993-8","article-title":"Intra-aortic balloon pump is associated with the lowest whereas Impella with the highest inpatient mortality and complications regardless of severity or hospital types","volume":"39","author":"Movahed MR","year":"2024","unstructured":"Movahed MR, Talle A, Hashemzadeh M. Intra-aortic balloon pump is associated with the lowest whereas Impella with the highest inpatient mortality and complications regardless of severity or hospital types. Cardiovasc Interv Ther. 2024;39:252\u201361.","journal-title":"Cardiovasc Interv Ther"},{"key":"ref16","author":"Sinha SS","year":"2025","unstructured":"Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;85:1618-41."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.21037\/atm-20-2171","article-title":"Short-term mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation, TandemHeart): a review","volume":"8","author":"Wong ASK","year":"2020","unstructured":"Wong ASK, Sin SWC. Short-term mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation, TandemHeart): a review. Ann Transl Med. 2020;8:829.","journal-title":"Ann Transl Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e008527","DOI":"10.1161\/CIRCHEARTFAILURE.121.008527","article-title":"Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice","volume":"14","author":"Baldetti L","year":"2021","unstructured":"Baldetti L, Pagnesi M, Gramegna M, Belletti A, Beneduce A, Pazzanese V, et al. Intra-Aortic Balloon Pumping in Acute Decompensated Heart Failure With Hypoperfusion: From Pathophysiology to Clinical Practice. Circ Heart Fail. 2021;14:e008527.","journal-title":"Circ Heart Fail"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.amjcard.2019.09.016","article-title":"Comparison of the Hemodynamic Response to Intra-Aortic Balloon Counterpulsation in Patients With Cardiogenic Shock Resulting from Acute Myocardial Infarction Versus Acute Decompensated Heart Failure","volume":"124","author":"Malick W","year":"2019","unstructured":"Malick W, Fried JA, Masoumi A, Nair A, Zuver A, Huang A, et al. Comparison of the Hemodynamic Response to Intra-Aortic Balloon Counterpulsation in Patients With Cardiogenic Shock Resulting from Acute Myocardial Infarction Versus Acute Decompensated Heart Failure. Am J Cardiol. 2019;124:1947\u201353.","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/CIRCULATIONAHA.112.098194","article-title":"A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study","volume":"126","author":"O'Neill WW","year":"2012","unstructured":"O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126:1717\u201327.","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2009.09.018","article-title":"Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry","volume":"54","author":"Sjauw KD","year":"2009","unstructured":"Sjauw KD, Konorza T, Erbel R, Danna PL, Viecca M, Minden HH, et al. Supported high-risk percutaneous coronary intervention with the Impella 2.5 device the Europella registry. J Am Coll Cardiol. 2009;54:2430\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.healun.2017.09.020","article-title":"Use of a percutaneous temporary circulatory support device as a bridge to decision during acute decompensation of advanced heart failure","volume":"37","author":"Hall SA","year":"2018","unstructured":"Hall SA, Uriel N, Carey SA, Edens M, Gong G, Esposito M, et al. Use of a percutaneous temporary circulatory support device as a bridge to decision during acute decompensation of advanced heart failure. J Heart Lung Transpl. 2018;37:100\u20136.","journal-title":"J Heart Lung Transpl"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e030819","DOI":"10.1161\/JAHA.123.030819","article-title":"Complications and Outcomes of Impella Treatment in Cardiogenic Shock Patients With and Without Acute Myocardial Infarction","volume":"12","author":"Saito Y","year":"2023","unstructured":"Saito Y, Tateishi K, Toda K, Matsumiya G, Kobayashi Y. Complications and Outcomes of Impella Treatment in Cardiogenic Shock Patients With and Without Acute Myocardial Infarction. J Am Heart Assoc. 2023;12:e030819.","journal-title":"J Am Heart Assoc"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1002\/ehf2.13546","article-title":"Outcome of patients with non-ischaemic cardiogenic shock supported by percutaneous left ventricular assist device","volume":"8","author":"Haurand JM","year":"2021","unstructured":"Haurand JM, Haberkorn S, Haschemi J, Oehler D, Aubin H, Akhyari P, et al. Outcome of patients with non-ischaemic cardiogenic shock supported by percutaneous left ventricular assist device. ESC Heart Fail. 2021;8:3594\u2013602.","journal-title":"ESC Heart Fail"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9887872\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9887872\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T17:55:50Z","timestamp":1784483750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9887872\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":24,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9887872\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,7,7]]},"subtype":"preprint"}}